Drug intelligence / Profile preview

HKRM-ACLP

Development stage: Unknown
Lead developer: Hong Kong Regen Medtech
Modality: Stem Cell Therapies → Cell Therapies
Administration: Subcutaneous

Overview

HKRM-ACLP is an allogeneic mesenchymal stem cell (MSC) therapy developed by Hong Kong Regen Medtech for the treatment of Acute-on-Chronic Liver Failure (ACLF). The program utilizes a proprietary Japan-origin MSC manufacturing platform and is produced in Hong Kong's first PIC/S GMP-licensed allogeneic MSC facility. Licensed from a Beijing-based stem cell company in 2025, HKRM-ACLP aims to address high unmet medical needs in Asia by leveraging the immunomodulatory and regenerative properties of MSCs to treat degenerative and immunological conditions. It is currently in Phase II clinical development.

Other names: HKRM-ACLP

Beyond the preview

Go deeper on HKRM-ACLP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HKRM-ACLP.

Explore the full profile